Key Takeaways
- Shares of Hims & Hers Health (HIMS) tumbled approximately 7% on Monday following the disclosure of a $300 million convertible senior notes offering.
- The convertible notes carry a maturity date of June 1, 2032, and will be sold exclusively to qualified institutional buyers through a private placement.
- Funds raised will support the company’s global expansion efforts, including financing the anticipated Eucalyptus acquisition set to finalize in mid-2026.
- Hims & Hers intends to deploy a portion of the capital for capped call transactions designed to minimize potential dilution for Class A shareholders.
- The initial purchasers received a 13-day option to acquire an additional $45 million in notes, potentially increasing the total offering to $345 million.
Shares of Hims & Hers Health (HIMS) tumbled nearly 7% during Monday’s trading session after the telehealth provider unveiled its intention to secure $300 million through a convertible senior notes offering maturing in 2032.
Hims & Hers Health, Inc., HIMS
The decline began in premarket hours, with shares falling close to 4% following the initial announcement. The downward pressure accelerated as regular trading commenced.
The convertible notes will be marketed exclusively to qualified institutional buyers through a private offering. Critical details including the interest rate and conversion price will be determined during the pricing process.
The notes will pay interest on a semi-annual basis and reach maturity on June 1, 2032, barring early repurchase, redemption, or conversion.
Bondholders will be granted conversion rights subject to specific conditions. Upon conversion, Hims & Hers retains the flexibility to settle obligations through cash payment, issuance of Class A common stock, or a combination of both methods.
Dilution Mitigation Through Capped Call Strategy
The telehealth company announced it will allocate a portion of the offering proceeds toward capped call transactions. This financial strategy aims to mitigate potential shareholder dilution that could result from note conversions into equity.
The underwriters received an option exercisable within 13 days to purchase up to $45 million in additional notes. Should this option be fully exercised, the aggregate offering size would reach $345 million.
The company gains the right to redeem the notes beginning June 6, 2029, contingent upon the Class A stock price surpassing 130% of the conversion price for a specified duration. Additionally, noteholders possess the right to demand cash repurchase under certain fundamental corporate change scenarios.
Funding International Growth and Australian Telehealth Acquisition
According to Hims & Hers, the capital will primarily provide financial flexibility to support its international expansion strategy. A key component involves financing the pending acquisition of Eucalyptus, a telehealth platform based in Australia.
The transaction involving Eucalyptus is projected to reach completion by mid-2026. Complete financial details of the acquisition have not been publicly revealed.
In addition to the acquisition, the company outlined plans to invest in technology infrastructure and fulfillment operations. The company also emphasized expanding AI capabilities and strengthening its integrated data ecosystem.
HIMS shares were down approximately 7.7% on Monday based on the most recent market data.
